{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:20:23Z","timestamp":1792272023031,"version":"4.4.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>In June 2013 a European Medicines Agency referral procedure concluded that diclofenac was associated with an elevated risk of acute cardiovascular events and contraindications, warnings, and changes to the product information were implemented across the European Union. This study measured the impact of the regulatory action on the prescribing of systemic diclofenac in Denmark, The Netherlands, England, and Scotland.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Quarterly time series analyses measuring diclofenac prescription initiation, discontinuation and switching to other systemic nonsteroidal anti\u2010inflammatory (NSAIDs), topical NSAIDs, paracetamol, opioids, and other chronic pain medication in those who discontinued diclofenac. Absolute effects were estimated using interrupted time series regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, diclofenac prescription initiations fell during the observation periods of all countries. Compared with Denmark where there appeared to be a more limited effect, the regulatory action was associated with significant immediate reductions in diclofenac initiation in The Netherlands (\u22120.42%, 95% CI, \u22120.66% to \u22120.18%), England (\u22120.09%, 95% CI, \u22120.11% to \u22120.08%), and Scotland (\u22120.67%, 95% CI, \u22120.79% to \u22120.55%); and falling trends in diclofenac initiation in the Netherlands (\u22120.03%, 95% CI, \u22120.06% to \u22120.01% per quarter) and Scotland (\u22120.04%, 95% CI, \u22120.05% to \u22120.02% per quarter). There was no significant impact on diclofenac discontinuation in any country. The regulatory action was associated with modest differences in switching to other pain medicines following diclofenac discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The regulatory action was associated with significant reductions in overall diclofenac initiation which varied by country and type of exposure. There was no impact on discontinuation and variable impact on switching.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4955","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T23:44:21Z","timestamp":1578095061000},"page":"296-305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands"],"prefix":"10.1002","volume":"29","author":[{"given":"Daniel R.","family":"Morales","sequence":"first","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve V.","family":"Morant","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-6669","authenticated-orcid":false,"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla S.","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S. F.","family":"Doney","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"Mitchell","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bennie","sequence":"additional","affiliation":[{"name":"Strathclyde Onstitute of Pharmacy and Biomedical Sciences University of Strathclyde  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[{"name":"Dept of Mathematics and Statistics University of Strathclyde  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-8708","authenticated-orcid":false,"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[{"name":"Dept of Clinical Pharmacology and Pharmacy University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5679","authenticated-orcid":false,"given":"Anton","family":"Pottegard","sequence":"additional","affiliation":[{"name":"Dept of Clinical Pharmacology and Pharmacy University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Thomsen","family":"Ernst","sequence":"additional","affiliation":[{"name":"Dept of Clinical Pharmacology and Pharmacy University of Southern Denmark  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzie","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Electronic Data Research and Innovation Service NHS National Services Scotland  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Morris","sequence":"additional","affiliation":[{"name":"Electronic Data Research and Innovation Service NHS National Services Scotland  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron M. C.","family":"Herings","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetty A.","family":"Overbeek","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Smits","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W. V.","family":"Flynn","sequence":"additional","affiliation":[{"name":"MEMO Research University of Dundee  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3463"},{"key":"e_1_2_9_4_1","unstructured":"New safety advice for diclofenac\u2014new measures aim to minimise cardiovascular risks.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_libra ry\/Referrals_ document\/Diclofenac\u2010containing_medicinal_products\/European_Commission_final_decision\/WC500155819.pdf (Accessed on May 30 2018)"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00283.x"},{"key":"e_1_2_9_7_1","unstructured":"New safety advice for diclofenac\u2014CMDh endorses PRAC recommendation.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Diclofenac-containing_medicinal_products\/Position_provided_by_CMDh\/WC500144853.pdf(Accessed on May 30 2018)"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw060"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"issue":"3","key":"e_1_2_9_12_1","first-page":"798","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Pottegard A","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl391"},{"key":"e_1_2_9_14_1","unstructured":"EU PAS Register. Impact of EU label changes for systemic diclofenac products: post\u2010referral prescribing trends. Available at:http:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=28936Accessed March 18 2019."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13469"},{"issue":"2","key":"e_1_2_9_17_1","article-title":"Impact of the World Health Organization Pain Treatment Guidelines and the European Medicines Agency Safety Recommendations on Nonsteroidal Anti\u2010Inflammatory Drug Use in Lithuania: An Observational Study","volume":"54","author":"Kasciu\u0161kevi\u010di\u016bt\u0117 S","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"e_1_2_9_18_1","unstructured":"Statistics for the annual sales of pharmaceuticals in Denmark. MEDSTAT. Available at:http:\/\/medstat.dk\/en\/viewDataTables\/medicineAndMedicalGroups\/%7B%22year%22:[%222013%22] %22region%22:[%220%22] %22gender%22:[%22A%22] %22ageGroup%22:[%22A%22] %22searchVariable%22:[%22sold_volume%22] %22errorMessages%22:[] %22atcCode%22:[%22M01A%22 %22M01AB05%22] %22sector%22:[%222%22]%7D (Accessed on 1stMarch 2019)"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.02.007"},{"key":"e_1_2_9_20_1","unstructured":"European Medicines Agency. Assessment report for Non\u2010Steroidal Anti\u2010Inflammatory Drugs (NSAIDs) and cardiovascular risk. Procedure no: EMEA\/H\/A\u20105(3)\/1319. Oct 2012. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/referral\/assessment-report-article-53-procedure-non-steroidal-anti-inflammatory-drugs-nsaids-cardiovascular_en.pdfAccessed 03\/10\/2019."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14104"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068976"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02650-z"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4955","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4955","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T04:26:26Z","timestamp":1694060786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1002\/pds.4955"],"URL":"https:\/\/doi.org\/10.1002\/pds.4955","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"2019-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}